<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2016-4-eng-140-147</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-822</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ПАРАМЕТРЫ МЕТАБОЛИЗМА И ГЕМОСТАЗА ПРИ ПРЕДИАБЕТЕ И ВПЕРВЫЕ ВЫЯВЛЕННОМ САХАРНОМ ДИАБЕТЕ 2 ТИПА</article-title><trans-title-group xml:lang="en"><trans-title>METABOLIC AND HEMOSTATIC PARAMETERS IN PRE-DIABETES AND NEWLY DIAGNOSED TYPE 2 DIABETES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Petrik</surname><given-names>G. G.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrik</surname><given-names>G. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Краснодар;</p><p>Краснодарский край</p></bio><bio xml:lang="en"><p>PhD, Docent Chair of Therapy N1, Krasnodar;</p><p>Krasnodar Region</p></bio><email xlink:type="simple">pgg@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Kosmacheva</surname><given-names>E. D.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosmacheva</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Краснодар;</p><p>Краснодарский край</p></bio><bio xml:lang="en"><p>Krasnodar;</p><p>Krasnodar Region</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Bratchik</surname><given-names>A. V.</given-names></name><name name-style="western" xml:lang="en"><surname>Bratchik</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Краснодарский край</p></bio><bio xml:lang="en"><p>Krasnodar Region</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Kudryashov</surname><given-names>R. O.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudryashov</surname><given-names>R. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Краснодар</p></bio><bio xml:lang="en"><p>Krasnodar</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Glushanova</surname><given-names>V. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Glushanova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Краснодарский край</p></bio><bio xml:lang="en"><p>Krasnodar Region</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Кубанский государственный медицинский университет Минздрава России;&#13;
Научно-исследовательский институт, областная клиническая больница им. С.В. Очаповского<country>Россия</country></aff><aff xml:lang="en">Kuban State Medical University of Ministry of Health;&#13;
S.V. Ochapovsky Research and Development Institute — Regional Clinical Hospital<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Научно-исследовательский институт, областная клиническая больница им. С.В. Очаповского<country>Россия</country></aff><aff xml:lang="en">S.V. Ochapovsky Research and Development Institute — Regional Clinical Hospital<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Кубанский государственный медицинский университет Минздрава России<country>Россия</country></aff><aff xml:lang="en">Kuban State Medical University of Ministry of Health<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>04</month><year>2016</year></pub-date><volume>0</volume><issue>4-eng</issue><issue-title>РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ</issue-title><fpage>140</fpage><lpage>147</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Petrik G.G., Kosmacheva E.D., Bratchik A.V., Kudryashov R.O., Glushanova V.A., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Petrik G.G., Kosmacheva E.D., Bratchik A.V., Kudryashov R.O., Glushanova V.A.</copyright-holder><copyright-holder xml:lang="en">Petrik G.G., Kosmacheva E.D., Bratchik A.V., Kudryashov R.O., Glushanova V.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/822">https://russjcardiol.elpub.ru/jour/article/view/822</self-uri><abstract><p>Метаболические изменения при сахарном диабете (СД) сопряжены с нарушениями гемостаза, последовательность вовлечения компонентов которого на ранних стадиях заболевания не определена.</p><sec><title>Цель</title><p>Цель. Изучение параметров метаболизма, гемостаза и характера их взаимоотношений при предиабете и впервые выявленном СД 2 типа (ВВ СД2).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Объектом исследования явились добровольцы в возрасте 40-65 лет считающие себя здоровыми и не получающие никакой медикаментозной терапии. У 46 из 170 обследованных выявлены нарушения углеводного обмена (НУО): 13 — нарушение гликемии натощак,17 нарушение толерантности к глюкозе и у 16 ВВ СД2. Контрольную группу составили 13 здоровых добровольцев с нормальной массой тела без признаков метаболически аномального фенотипа. Во всех контингентах исследованы параметры метаболизма (углеводный, липидный, белковый обмен, трансаминазы печени) и тромбоцитарно-плазменного гемостаза (средний объем тромбоцитов, ADP- и коллаген-индуцированная агрегация тромбоцитов, коагулограмма, фибриноген, плазминоген). Определены особенности инициирующих влияний измененных параметров метаболизма на различные компоненты гемостаза при предиабете и ВВ СД2.</p></sec><sec><title>Результаты</title><p>Результаты. Концентрация инсулина, С-пептида, HOMA-IR, общее содержание холестерина были повышены в группах с нарушением углеводного обмена. АДФ и коллагеном-вызванной агрегацию тромбоцитов, фибриноген так же были повышены при НУО, однако эти изменения не были статистически значимы. Средний объем тромбоцитов и плазминогена имели склонность к увеличению на стадии предиабета и продемонстрировали статистически значимое увеличение при ВВ СД2.</p></sec><sec><title>Заключение</title><p>Заключение. Метаболические нарушения на стадии предиабета инициируют изменения тромбоцитарного гемостаза и фибринолиза. При ВВ СД2 увеличение MPV и повышение концентрации плазминогена принимают значимый характер.</p></sec></abstract><trans-abstract xml:lang="en"><p>Metabolic changes in diabetes mellitus are associated with hemostatic disorders. However, the sequence of hemostatic events in the early stages of disease remains unclear.</p><sec><title>Aim</title><p>Aim. To assess metabolic and hemostatic parameters and their interaction in pre-diabetes and newly diagnosed type 2 diabetes mellitus (ND T2DM).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study enrolled volunteers of 40 to 65 years who considered themselves healthy and did not get any medication therapy. Of 170 examined individuals, 46 had impaired carbohydrate exchange (ICE) — 13 with impaired fasting glucose, 17 — impaired glucose tolerance and 16 with ND T2DM. The control group comprised healthy volunteers with normal body mass index and without signs of metabolic abnormalities. The metabolic (carbohydrate, lipid, protein exchange, hepatic transaminase), platelet and plasma hemostatic parameters (mean platelet volume, ADP- &amp;collagen-induced platelet aggregation, coagulation profile, fibrinogen, plasminogen) were investigated. We identified the peculiarities initiating impact of changed parameters on different hemostatic components in patients with pre-diabetes and ND T2DM.</p></sec><sec><title>Results</title><p>Results. Concentration of insulin, C-peptide, Homa-IR, total cholesterol demonstrated increase in groups with ICE. ADP-induced platelet aggregation, fibrinogen increased in ICE, however these changes were not statistically significant. Mean platelet volume and plasminogen had the tendency to be elevated in pre-diabetes and demonstrated significant increase in ND T2DM.</p></sec><sec><title>Conclusion</title><p>Conclusion. Metabolic disorders in prediabetic stage initiate changes in platelet hemostasis and fibrinolysis. The increase of MPV and higher concentrations of plasminogen are considered to be significant in ND T2DM.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>предиабет</kwd><kwd>впервые выявленный сахарный диабет 2 типа</kwd><kwd>метаболические нарушения</kwd><kwd>гемостаз — тромбоцитарный</kwd><kwd>коагуляционный</kwd><kwd>фибринолиз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pre-diabetes</kwd><kwd>newly diagnosed type 2 diabetes mellitus</kwd><kwd>metabolic disorders</kwd><kwd>hemostasis — platelets</kwd><kwd>coagulation</kwd><kwd>fibrinolysis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Wood D., Ralston J, Reddy K.S. The World Heart Federation’s vision for worldwide cardiovascular disease prevention. Lancet 2015; 386: 399–402.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Wood D., Ralston J, Reddy K.S. The World Heart Federation’s vision for worldwide cardiovascular disease prevention. Lancet 2015; 386: 399–402.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">International Diabetes Federation. Diabetes Atlas 2014. https://www.idf.org/sites/default/files/attachments/2014_4_Makaroff.pdf</mixed-citation><mixed-citation xml:lang="en">International Diabetes Federation. Diabetes Atlas 2014. https://www.idf.org/sites/default/files/attachments/2014_4_Makaroff.pdf</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ferreiro JL, Gómez-Hospital1 JA, Angiolillo AJ. Platelet abnormalities in diabetes mellitus. Diabetes &amp; Vascular Disease Research 2010; 7(4): 251–9.</mixed-citation><mixed-citation xml:lang="en">Ferreiro JL, Gómez-Hospital1 JA, Angiolillo AJ. Platelet abnormalities in diabetes mellitus. Diabetes &amp; Vascular Disease Research 2010; 7(4): 251–9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tabit CE, Chung WB, Hamburg NM,Vita JA.Endothelialdysfunction in diabetes mellitus: molecular mechanisms and clinical. Reviews in Endocrine and Metabolic Disorders 2010; 11(1): 61–74.</mixed-citation><mixed-citation xml:lang="en">Tabit CE, Chung WB, Hamburg NM,Vita JA.Endothelialdysfunction in diabetes mellitus: molecular mechanisms and clinical. Reviews in Endocrine and Metabolic Disorders 2010; 11(1): 61–74.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Vazzana N, Ranalli P, Cuccurullo C, Davi G. Diabetes mellitus and thrombosis. Thromb Res 2012; 129: 371-7.</mixed-citation><mixed-citation xml:lang="en">Vazzana N, Ranalli P, Cuccurullo C, Davi G. Diabetes mellitus and thrombosis. Thromb Res 2012; 129: 371-7.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999.</mixed-citation><mixed-citation xml:lang="en">World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization (WHO), Abbreviated report of aWHO consultation. Use of glycated hemoglobin (HbA1c) in the diagnosis if diabetes mellitus. 2011.</mixed-citation><mixed-citation xml:lang="en">World Health Organization (WHO), Abbreviated report of aWHO consultation. Use of glycated hemoglobin (HbA1c) in the diagnosis if diabetes mellitus. 2011.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2015; 38(Suppl 1): S8-16.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2015; 38(Suppl 1): S8-16.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013; 34: 2159–219.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013; 34: 2159–219.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Williams Texbook of Endocrinology, 11th edition. Elsevier Ltd., 2008: 1589-631.</mixed-citation><mixed-citation xml:lang="en">Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Williams Texbook of Endocrinology, 11th edition. Elsevier Ltd., 2008: 1589-631.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bloomgarden ZT. Cardiovascular Disease in Diabetes. Diabetes Care. 2010; 33: 49–54.</mixed-citation><mixed-citation xml:lang="en">Bloomgarden ZT. Cardiovascular Disease in Diabetes. Diabetes Care. 2010; 33: 49–54.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ryden L., Co-Chairperson, Standl E. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. Eur Heart J. 2013; 34: 3035-87.</mixed-citation><mixed-citation xml:lang="en">Ryden L., Co-Chairperson, Standl E. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. Eur Heart J. 2013; 34: 3035-87.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am.J. Med. 2003; 115(8A): 62-8.</mixed-citation><mixed-citation xml:lang="en">Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am.J. Med. 2003; 115(8A): 62-8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Juhan-Vague I, Roul C, Alessi MC, et al. Increase plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients: relationship with plasma insulin. Thromb. Haemost. 1989; 61:370-3.</mixed-citation><mixed-citation xml:lang="en">Juhan-Vague I, Roul C, Alessi MC, et al. Increase plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients: relationship with plasma insulin. Thromb. Haemost. 1989; 61:370-3.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Geiger M, Binder BR. Plasminogen activation in diabetes mellitus. Enzyme 1988; 40: 149-57.</mixed-citation><mixed-citation xml:lang="en">Geiger M, Binder BR. Plasminogen activation in diabetes mellitus. Enzyme 1988; 40: 149-57.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Meigs JB, O’donnell CJ, Tofler GH et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes : the Framingham Offspring Study. Diabetes. 2006; 55: 530–7.</mixed-citation><mixed-citation xml:lang="en">Meigs JB, O’donnell CJ, Tofler GH et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes : the Framingham Offspring Study. Diabetes. 2006; 55: 530–7.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Folsom A, Wu K, Rasumussen M. Determinants of population changes in fibrinogen and factor VII over 6 year. Arteriosclerosis, Trombosis and Vasculare Biology. 2000; .20: 601-6.</mixed-citation><mixed-citation xml:lang="en">Folsom A, Wu K, Rasumussen M. Determinants of population changes in fibrinogen and factor VII over 6 year. Arteriosclerosis, Trombosis and Vasculare Biology. 2000; .20: 601-6.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Corrado E, Rizzo M, Muratori I. Assotiation of elevated fibrinogen and CRP levels with carotid lesions in patiets with newly diagnosed hypertensionor type 2 diabetes. Arch Med Res. 2006; 3798: 1004-9.</mixed-citation><mixed-citation xml:lang="en">Corrado E, Rizzo M, Muratori I. Assotiation of elevated fibrinogen and CRP levels with carotid lesions in patiets with newly diagnosed hypertensionor type 2 diabetes. Arch Med Res. 2006; 3798: 1004-9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Dunn E, Ariens R, Grant P. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005; 48: 1198–1206.</mixed-citation><mixed-citation xml:lang="en">Dunn E, Ariens R, Grant P. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005; 48: 1198–1206.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Coban E, Yazicioglu G, Ozdogan M. Platelet activation in subjects with subclinical hypothyroidism. Med SciMonit. 2007; 13: 211-4.</mixed-citation><mixed-citation xml:lang="en">Coban E, Yazicioglu G, Ozdogan M. Platelet activation in subjects with subclinical hypothyroidism. Med SciMonit. 2007; 13: 211-4.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Tavassoli M. Megakaryocyte-platelet axis and the process of platelet formation and release. Blood. 1980; 55: 537-45.</mixed-citation><mixed-citation xml:lang="en">Tavassoli M. Megakaryocyte-platelet axis and the process of platelet formation and release. Blood. 1980; 55: 537-45.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Michno A, Bielarezyk H, Pawetczyk T, Jan Kowska-Kulawy A. Alterations of adenine nuckleotide metabolism and function of blood platelets in patients with diabetes. Diabetes. 2007: 56: 462-7.</mixed-citation><mixed-citation xml:lang="en">Michno A, Bielarezyk H, Pawetczyk T, Jan Kowska-Kulawy A. Alterations of adenine nuckleotide metabolism and function of blood platelets in patients with diabetes. Diabetes. 2007: 56: 462-7.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Negrev N. The effect of insulin in thrombocytopoiesis and thrombocytopoietin biosynthesis in rats. Exp.Med.Morfol. 1990; 29(4): 24-7.</mixed-citation><mixed-citation xml:lang="en">Negrev N. The effect of insulin in thrombocytopoiesis and thrombocytopoietin biosynthesis in rats. Exp.Med.Morfol. 1990; 29(4): 24-7.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Vinik AI, Tomris E, Roger N. Platelet disfunction in type 2 diabetes. Diabetes. 2001; 24 (8): 1476-85.</mixed-citation><mixed-citation xml:lang="en">Vinik AI, Tomris E, Roger N. Platelet disfunction in type 2 diabetes. Diabetes. 2001; 24 (8): 1476-85.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Keating FK, Sobel B E, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes. Am. J. Cardiol. 2003; 92:1362–5.</mixed-citation><mixed-citation xml:lang="en">Keating FK, Sobel B E, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes. Am. J. Cardiol. 2003; 92:1362–5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider DJ. Factors Contributing to Increased Platelet Reactivity in People With Diabetes. Diabetes Care. 2009; 32: 525-7.</mixed-citation><mixed-citation xml:lang="en">Schneider DJ. Factors Contributing to Increased Platelet Reactivity in People With Diabetes. Diabetes Care. 2009; 32: 525-7.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Michelson A. Platelets. Second Edition.— Amsterdam, Boston, Heidelberg et al.: Academic Press. Elserver Inc., 2007: 697-712.</mixed-citation><mixed-citation xml:lang="en">Michelson A. Platelets. Second Edition.— Amsterdam, Boston, Heidelberg et al.: Academic Press. Elserver Inc., 2007: 697-712.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">McLeod AJ, Johnson M. Suckling KE, Walton P. Enchanced phospholipase A2 activity in cholesterol-enriched platelets from rabbits FED a cholesterdenriched platelets from rebbi tsFEDacholesterolenricheddiet. Throm. Haemost. 1981; 46(1): 278.</mixed-citation><mixed-citation xml:lang="en">McLeod AJ, Johnson M. Suckling KE, Walton P. Enchanced phospholipase A2 activity in cholesterol-enriched platelets from rabbits FED a cholesterdenriched platelets from rebbi tsFEDacholesterolenricheddiet. Throm. Haemost. 1981; 46(1): 278.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Dutu A, Gligore V, Hincu N, Podut A. Aspeetecorelativeintrelipidelesericefunctiiletrombocit aresiangiopatic in diabotulzaharef. Med.interna (Buc.) — 1972; 24(1): 81-6</mixed-citation><mixed-citation xml:lang="en">Dutu A, Gligore V, Hincu N, Podut A. Aspeetecorelativeintrelipidelesericefunctiiletrombocit aresiangiopatic in diabotulzaharef. Med.interna (Buc.) — 1972; 24(1): 81-6</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Jovan M, Dusan D, Dragan M.et al. Agregacijathrombocita u bolesnika s diabetes mellitus ihyperlipoproteinemiajomtipa IV. Diabetol. Croat. 1979; 8(3): 227-49.</mixed-citation><mixed-citation xml:lang="en">Jovan M, Dusan D, Dragan M.et al. Agregacijathrombocita u bolesnika s diabetes mellitus ihyperlipoproteinemiajomtipa IV. Diabetol. Croat. 1979; 8(3): 227-49.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. CurrMol Med. 2005; 5: 323-32.</mixed-citation><mixed-citation xml:lang="en">Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. CurrMol Med. 2005; 5: 323-32.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Barillari G, Fabbro E, Pasca S, Bigotto E. Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population. Blood Coagul. Fibrinolysis. 2009; 20: 290-6.</mixed-citation><mixed-citation xml:lang="en">Barillari G, Fabbro E, Pasca S, Bigotto E. Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population. Blood Coagul. Fibrinolysis. 2009; 20: 290-6.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Maschirow L, Khalaf K, Al-Aubaidy HA, Jelinek HF. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes.— Biomarkers as a possible tool for early disease detection for rural screening. ClinBiochem. 2015;48(9): 581-5.</mixed-citation><mixed-citation xml:lang="en">Maschirow L, Khalaf K, Al-Aubaidy HA, Jelinek HF. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes.— Biomarkers as a possible tool for early disease detection for rural screening. ClinBiochem. 2015;48(9): 581-5.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
